Zoetis Inc. reported a total revenue of $9.467 billion for the fiscal year ended December 31, 2025, marking a 2% increase from $9.256 billion in 2024. The company's net income attributable to Zoetis rose to $2.673 billion, an 8% increase compared to $2.486 billion in the previous year. Adjusted net income, a non-GAAP measure, also increased by 6% to $2.847 billion. The growth in revenue was primarily driven by a 4% price increase and a 1% volume growth from in-line products, although this was partially offset by a 3% volume decrease due to the divestiture of the medicated feed additive product portfolio.
In terms of operational segments, the U.S. generated $5.097 billion in revenue, slightly up from $5.074 billion in 2024, while the International segment saw a revenue increase to $4.254 billion from $4.102 billion. Companion animal products accounted for approximately 70% of total revenue, with livestock products contributing around 29%. The company also noted that its top five products contributed to 42% of total revenue, with Simparica/Simparica Trio and Apoquel/Apoquel Chewable being the leading contributors.
Strategically, Zoetis has been active in acquisitions and product development. In 2025, the company acquired Veterinary Pathology Group, enhancing its diagnostic capabilities. The company also completed the divestiture of its medicated feed additive portfolio in late 2024, which has since been excluded from its major product categories. Additionally, Zoetis has focused on expanding its product lines, including the launch of new therapies and vaccines, which are expected to drive future growth.
Operationally, Zoetis employed approximately 14,500 people globally as of December 31, 2025, with a significant portion dedicated to research and development (R&D). The company invested $698 million in R&D during the year, reflecting a commitment to innovation in animal health. The company anticipates continued growth in both companion animal and livestock markets, driven by increasing pet ownership, economic development, and the demand for high-quality animal protein. Looking ahead, Zoetis expects to align the fiscal years of its international subsidiaries with its U.S. operations in 2026, which may further streamline reporting and operational efficiency.
About Zoetis Inc.
Zoetis Inc. is a global leader in animal health, specializing in the discovery, development, manufacturing, and commercialization of medicines, vaccines, diagnostics, biodevices, and genetic tests for companion animals and livestock. Its diversified portfolio serves veterinarians, pet owners, and livestock producers worldwide, emphasizing innovation, product lifecycle extension, and regulatory compliance to improve animal welfare, food safety, and sustainability across major markets.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.